A website dedicated to the world of M&A – transactions, ideas, insights and other relevant M&A-related resources.
If you have been reading about mergers and acquisitions or have spoken lately with investment bankers or private equity fund managers, chances are that you’ve heard about roll-up acquisitions – or roll-ups. What’s that all about, you might think. Simple. The basic…
On October 21, 2015, Western Digital () announced its $19Bn acquisition of SanDisk (). Although not having any particular interest in the sector or the stocks, I’ve been following WDC’s stock from time to time out of curiosity. Given today’s ever-growing interest for…
What to do when your home market is saturated, stagnating or, worse, declining? In many cases, the answer is: Enter other markets. Traditionally, North American and Western European companies have favored developed markets in their international expansion. After all, many will tell you,…
There’s a lot of hype about deal making… as in finding a target and negotiating a transaction to a successful closing. Unfortunately, more often than not, that’s where the project will end in the mind of an inexperienced Buyer… and, therefore, that’s also…
Francois Hollande was elected thanks to its populist-yet-not-overly-extremist approach themed ‘let’s blame the riches for everything we can’. It’s therefore no surprise that his government has led many (most???) successful entrepreneurs to reside in neighboring countries or that his own prime minister…
Leverage Buy-Out, or LBO, is often depicted as a nifty way to package large transactions with limited risks. In the recent years, we see, hear and read about it all the time in the news with multi billion Dollar deals involving an…
Businesses follow a general growth trend but, much like people, each company is unique and follows its own trajectory. Some grow large, others remain small, some die young while others live over centuries. Again, much like people, a few have long and happy…
Teva Pharmaceuticals () is no less than the world’s #1 drug company in the Generics segment. For those who still wonder, Generics, in short, are drugs made by plants others than those having developed – and patented – the active ingredient. New…
Recently, as a sell-side advisor, I met with advisors of a buyer, hired after a non-binding offer had been signed. They had reviewed all documents shared in the data room and had had a rather extensive brief from their client as to what…
Today’s Pharma big deal is in the compounded drug segment. AmerisourceBergen, not at all shy when it comes to acquisitions, announced its acquisition of PharMEDium Healthcare Holdings from Private Equity Fund Clayton, Dubilier & Rice for a mere $2.575 Billion. More than a good exit for…
By now, most people have heard about Bitcoin, although many probably still don’t know much about it, other than, maybe, the fact that it’s the currency that was used for transactions done on dark web’s Silk Road (making in the process the US…
The end of a quarter usually means, for those of us in the deal space, receiving various emails updating us on global M&A activities. Today was no exception with, notably, Thomson Reuters and Merrill DataSite reps hitting my inbox with links to…